Skip to main content
SpringerLink
Log in

Survey of Data Package and Sample Size of Comparative Clinical Studies for Biosimilar Developments from PMDA Assessments

  • Original Research Article
  • Published:
Pharmaceutical Medicine Aims and scope Submit manuscript

Abstract

Background

The Japanese biosimilar guideline requires that the sponsors conduct clinical studies such as comparative pharmacokinetic (PK), pharmacodynamic (PD), or efficacy studies. In each biosimilar development, the sponsors consider the clinical data package, and thus clinical data packages vary among biosimilar developments.

Objectives

The aim of this study was to elucidate the clinical data packages for the biosimilars approved in Japan. The details of clinical data packages and sample size for the regulatory approvals of biosimilars in Japan was reported.

Methods

We surveyed the clinical data packages and sample size based on the Pharmaceuticals and Medical Devices Agency (PMDA) website review reports between 2009 and 2023.

Results

Twenty-four biosimilars have been approved based on the comparative PK and efficacy studies, 10 biosimilars have been approved based on the comparative PK/PD study, and one biosimilar has been approved based on the comparative efficacy study. Regarding the sample size, comparative PK studies were conducted in healthy volunteers or patients for up to 300 cases, although the majority enrolled only 1–100 cases (68.1%, 32/47). Comparative PD studies enrolling 1–30, 31–60, and 61–90 cases totaled 4, 7, and 4 cases, respectively. Finally, comparative efficacy studies enrolling 1–300, 301–600, and 601–900 totaled 6, 10, and 11 cases, respectively. In particular, the oncology and rheumatology areas were the first and second disease areas recruiting 601–900 patients.

Conclusion

Large numbers of patients were enrolled to conduct a comparative efficacy study. Efficient biosimilar development should be considered on the basis of the accumulation of scientific understanding of comparable features of biosimilars and their development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ministry of Health, Labour and Welfare. Guideline for ensuring quality, safety, and efficacy of biosimilars. 2020. https://www.pmda.go.jp/files/000267479.pdf. Accessed 27 Mar 2024.

  2. US FDA. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. https://www.fda.gov/media/82647/download. Accessed 9 Oct 2023.

  3. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed 9 Oct 2023.

  4. Schiestl M, Ranganna G, Watson K, Jung B, Roth K, Capsius B, et al. The path towards a tailored clinical biosimilar development. BioDrugs. 2020;34(3):297–306. https://doi.org/10.1007/s40259-020-00422-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cohen HP, Turner M, McCabe D, Woollett GR. Future evolution of biosimilar development by application of current science and available evidence: the developer’s perspective. BioDrugs. 2023;37(5):583–93. https://doi.org/10.1007/s40259-023-00619-0.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Medicines and Healthcare products Regulatory Agency. Guidance on the licensing of biosimilar products. 2022. https://www.gov.uk/government/publications/guidance-on-the-licensing-of-biosimilar-products/guidance-on-the-licensing-of-biosimilar-products. Accessed 15 Oct 2023.

  7. World Health Organization. Guidelines on evaluation of biosimilars. 2022. https://cdn.who.int/media/docs/default-source/biologicals/annex-3---who-guidelines-on-evaluation-of-biosimilars---sj-ik-5-may-2022.pdf?sfvrsn=9b2fa6d2_1&download=true. Accessed 15 Oct 2023.

  8. Pfizer. Let’s see how biosimilars are developed. https://www.pfizerbiosimilars.com/biosimilars-development. Accessed 9 Oct 2023.

  9. McKinsey & Company. Three imperatives for R&D in biosimilars. 2022. https://www.mckinsey.com/industries/life-sciences/our-insights/three-imperatives-for-r-and-d-in-biosimilars. Accessed 9 Oct 2023.

  10. Moore TJ, Mouslim MC, Blunt JL, Alexander GC, Shermock KM. Assessment of availability, clinical testing, and US Food and Drug Administration review of biosimilar biologic products. JAMA Intern Med. 2021;181(1):52–60. https://doi.org/10.1001/jamainternmed.2020.3997.

    Article  CAS  PubMed  Google Scholar 

  11. Kuribayashi R, Nakano A, Hariu A, Kishioka Y, Honda F. Historical overview of regulatory approvals and PMDA’s assessments for biosimilar products in Japan during 2009–2022. BioDrugs. 2023;37(4):443–51. https://doi.org/10.1007/s40259-023-00605-6.

    Article  PubMed  Google Scholar 

  12. Pharmaceuticals and Medical Devices Agency. Search for pharmaceutical medicine information. https://www.pmda.go.jp/PmdaSearch/iyakuSearch. Accessed 9 Oct 2023 (in Japanese).

  13. Pharmaceuticals and Medical Devices Agency. Review report for Somatropin BS SC Injection [Sandoz]. 2009. https://www.pmda.go.jp/drugs/2009/P200900093/270428000_22100AMX01031000_A100_2.pdf. Accessed 9 Oct 2023 (in Japanese).

  14. Pharmaceuticals and Medical Devices Agency. Review report for Epoetin alfa BS Injection [JCR. 2010. https://www.pmda.go.jp/drugs/2009/P200900068/530210000_22200AMX00238000_A100_1.pdf. Accessed 9 Oct 2023 (in Japanese).

  15. Mohri Z. Development of glycoprotein medicinal product: Road to marketing approval of the first biosimilar recombinant erythropoietin in Japan. Trends Glycosci Glycotechnol 2013;25(145):179–98. https://www.jstage.jst.go.jp/article/tigg/25/145/25_179/_pdf.

  16. Pharmaceuticals and Medical Devices Agency. Review report for Filgrastim BS Injection (Mochida) and [F]. 2012. https://www.pmda.go.jp/drugs/2012/P201200149/790005000_22400AMX01419000_A100_2.pdf. Accessed 9 Oct 2023 (in Japanese).

  17. Matsuguma K, Matsuki S, Eunhee C, Watanabe A, Tanaka A, Sakamoto K, et al. Pharmacokinetics and pharmacodynamics of FSK0808 and Gran after single intravenous drip administration or single subcutaneous administration: comparative study in healthy Japanese adult male subjects. Drug Dev Ind Pharm. 2015;41(3):470–5. https://doi.org/10.3109/03639045.2013.879721.

    Article  CAS  PubMed  Google Scholar 

  18. Matsuguma K, Matsuki S, Sakamoto K, Shiramoto M, Nakagawa M, Kimura M, et al. A comparative pharmacokinetic and pharmacodynamic study of FSK0808 versus reference filgrastim after repeated subcutaneous administration in healthy Japanese men. Clin Pharmacol Drug Dev. 2015;4(2):99–104. https://doi.org/10.1002/cpdd.178.

    Article  CAS  PubMed  Google Scholar 

  19. Pharmaceuticals and Medical Devices Agency. Review report for Filgrastim BS Injection [NK] and [Teva]. 2013. https://www.pmda.go.jp/drugs/2013/P201300017/530191000_22500AMX00855_A100_1.pdf. Accessed 9 Oct 2023 (in Japanese).

  20. Pharmaceuticals and Medical Devices Agency. Review report for Filgrastim BS Injection [Sandoz]. 2013. https://www.pmda.go.jp/drugs/2014/P201400028/270428000_22600AMX00524000_A100_1.pdf. Accessed 9 Oct 2023 (in Japanese).

  21. Pharmaceuticals and Medical Devices Agency. Review report for Infliximab BS IV Infusion [NK] and [CTH]. 2014. https://www.pmda.go.jp/drugs/2014/P201400086/530191000_22600AMX00758_A100_1.pdf. Accessed 9 Oct 2023 (in Japanese).

  22. Takeuchi T, Yamanaka H, Tanaka Y, Sakurai T, Saito K, Ohtsubo H, et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2015;25(6):817–24. https://doi.org/10.3109/14397595.2015.1022297.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Pharmaceuticals and Medical Devices Agency. Review report for Infliximab BS IV Infusion [Ayumi] and [Nichiiko]. 2017. https://www.pmda.go.jp/drugs/2014/P201400086/530191000_22600AMX00758_A100_1.pdf. Accessed 9 Oct 2023 (in Japanese).

  24. Pharmaceuticals and Medical Devices Agency. Review report for Infliximab BS IV Infusion [Pfizer]. 2018. https://www.pmda.go.jp/drugs/2018/P20180604002/671450000_23000AMX00482000_A100_1.pdf. Accessed 9 Oct 2023 (in Japanese).

  25. Palaparthy R, Udata C, Hua SY, Yin D, Cai CH, Salts S, et al. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537–01). Expert Rev Clin Immunol. 2018;14(4):329–36. https://doi.org/10.1080/1744666X.2018.1446829.

    Article  CAS  PubMed  Google Scholar 

  26. Pharmaceuticals and Medical Devices Agency. Review report for Insulin glargine BS Injection [Lilly]. 2014. https://www.pmda.go.jp/drugs/2014/P201400152/530471000_22600AMX01373_A100_1.pdf. Accessed 9 Oct 2023 (in Japanese).

  27. Linnebjerg H, Lam EC, Seger ME, Coutant D, Chua L, Chong CL, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: Three randomized euglycemic clamp studies. Diabetes Care. 2015;38(12):2226–33. https://doi.org/10.2337/dc14-2623.

    Article  CAS  PubMed  Google Scholar 

  28. Pharmaceuticals and Medical Devices Agency. Review report for Insulin glargine BS Injection [FFP]. 2016. https://www.pmda.go.jp/drugs/2016/P20160421001/671423000_22800AMX00368_A100_1.pdf Accessed 9 Oct 2023 (in Japanese).

  29. Pharmaceuticals and Medical Devices Agency. Review report for Rituximab BS IV Infusion [KHK]. 2017. https://www.pmda.go.jp/drugs/2017/P20171024002/270428000_22900AMX00970_A100_3.pdf Accessed 9 Oct 2023 (in Japanese).

  30. Pharmaceuticals and Medical Devices Agency. Review report for Rituximab BS IV Infusion [Pfizer]. 2019. https://www.pmda.go.jp/drugs/2019/P20190918002/671450000_30100AMX00259_A100_1.pdf Accessed 9 Oct 2023 (in Japanese).

  31. Cohen S, Emery P, Greenwald M, Yin D, Becker JC, Melia LA, et al. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. Br J Clin Pharmacol. 2016;82(1):129–38. https://doi.org/10.1111/bcp.12916.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Pharmaceuticals and Medical Devices Agency. Review report for Etanercept BS SC Injection [MA]. 2018. https://www.pmda.go.jp/drugs/2018/P20180207002/790005000_23000AMX00005_A100_1.pdf. Accessed 10 Oct 2023 (in Japanese).

  33. Pharmaceuticals and Medical Devices Agency. Review report for Etanercept BS SC Injection [TY] and [Nichiiko]. 2019. https://www.pmda.go.jp/drugs/2019/P20190226001/890640000_23100AMX00304_A100_1.pdf. Accessed 10 Oct 2023 (in Japanese).

  34. Pharmaceuticals and Medical Devices Agency. Review report for Trastuzumab BS IV Infusion [NK] and [CTH]. 2018. https://www.pmda.go.jp/drugs/2018/P20180314003/530191000_5122908013560_A100_1.pdf. Accessed 10 Oct 2023 (in Japanese).

  35. Esteva FJ, Stebbing J, Wood-Horrall RN, Winkle PJ, Lee SY, Lee SJ. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Cancer Chemother Pharmacol. 2018;81(3):505–14. https://doi.org/10.1007/s00280-017-3510-7.

    Article  CAS  PubMed  Google Scholar 

  36. Pharmaceuticals and Medical Devices Agency. Review report for Trastuzumab BS IV Infusion [Daiichi sankyo]. 2018. https://www.pmda.go.jp/drugs/2018/P20181017001/430574000_23000AMX00802_A100_2.pdf. Accessed 10 Oct 2023 (in Japanese).

  37. Hanes V, Chow V, Zhang N, Markus R. A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects. Cancer Chemother Pharmacol. 2017;79(5):881–8. https://doi.org/10.1007/s00280-017-3286-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Pharmaceuticals and Medical Devices Agency. Review report for Trastuzumab BS IV Infusion [Pfizer]. 2018. https://www.pmda.go.jp/drugs/2018/P20181012001/671450000_23000AMX00800_A100_1.pdf. Accessed 10 Oct 2023 (in Japanese).

  39. Yin D, Barker KB, Li R, Meng X, Reich SD, Ricart AD, et al. A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327–01). Br J Clin Pharmacol. 2014;78(6):1281–90. https://doi.org/10.1111/bcp.12464.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Pharmaceuticals and Medical Devices Agency. Review report for Agalsidase Beta BS IV Infusion [JCR]. 2018. https://www.pmda.go.jp/drugs/2018/P20181017002/530210000_23000AMX00804000_A100_1.pdf. Accessed 11 Oct 2023 (in Japanese).

  41. Nakamura K, Kawashima S, Tozawa H, Yamaoka M, Yamamoto T, Tanaka N, et al. Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase I and II/III clinical studies. Mol Genet Metab. 2020;130(3):215–24. https://doi.org/10.1016/j.ymgme.2020.04.003.

    Article  CAS  PubMed  Google Scholar 

  42. Pharmaceuticals and Medical Devices Agency. Review report for Bevacizumab BS IV Infusion [Pfizer]. 2019. https://www.pmda.go.jp/drugs/2019/P20190524001/671450000_30100AMX00023_A100_2.pdf. Accessed 13 Oct 2023 (in Japanese).

  43. Knight B, Rassam D, Liao S, Ewesuedo R. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers. Cancer Chemother Pharmacol. 2016;77(4):839–46. https://doi.org/10.1007/s00280-016-3001-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Pharmaceuticals and Medical Devices Agency. Review report for Bevacizumab BS IV Infusion [Daiichi sankyo]. 2019. https://www.pmda.go.jp/drugs/2019/P20191003001/430574000_30100AMX00289_A100_1.pdf. Accessed 13 Oct 2023 (in Japanese).

  45. Hanes V, Chow V, Pan Z, Markus R. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects. Cancer Chemother Pharmacol. 2018;82(5):899–905. https://doi.org/10.1007/s00280-018-3695-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Markus R, Chow V, Pan Z, Hanes V. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. Cancer Chemother Pharmacol. 2017;80(4):755–63. https://doi.org/10.1007/s00280-017-3416-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Pharmaceuticals and Medical Devices Agency. Review report for Bevacizumab BS IV Infusion [Nichiiko]. 2022. https://www.pmda.go.jp/drugs/2021/P20211223003/530169000_30400AMX00004_A100_1.pdf. Accessed 13 Oct 2023 (in Japanese).

  48. Eto T, Karasuyama Y, González V, Del Campo GA. A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers. Cancer Chemother Pharmacol. 2021;88(4):713–22. https://doi.org/10.1007/s00280-021-04324-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Pharmaceuticals and Medical Devices Agency. Review report for Bevacizumab BS IV Infusion [CTNK]. 2022. https://www.pmda.go.jp/drugs/2022/P20221004002/530191000_30400AMX00418_A100_1.pdf. Accessed 13 Oct 2023 (in Japanese).

  50. Pharmaceuticals and Medical Devices Agency. Review report for Teriparatide BS SC Injection [Mochida]. 2019. https://www.pmda.go.jp/drugs/2019/P20191011002/790005000_30100AMX00291_A100_1.pdf. Accessed 13 Oct 2023 (in Japanese).

  51. Takács I, Jókai E, Kováts DE, Aradi I. The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic/pharmacodynamic study. Osteoporos Int. 2019;30(3):675–83. https://doi.org/10.1007/s00198-018-4741-0.

    Article  CAS  PubMed  Google Scholar 

  52. Pharmaceuticals and Medical Devices Agency. Review report for Darbepoetin alfa BS Injection [JCR]. 2019. https://www.pmda.go.jp/drugs/2019/P20191011004/530210000_30100AMX00271000_A101_1.pdf. Accessed 13 Oct 2023 (in Japanese).

  53. Pharmaceuticals and Medical Devices Agency. Review report for Darbepoetin alfa BS Injection [Sanwa]. 2019. https://www.pmda.go.jp/drugs/2019/P20191011001/300297000_30100AMX00262_A100_2.pdf. Accessed 13 Oct 2023 (in Japanese).

  54. Pharmaceuticals and Medical Devices Agency. Review report for Darbepoetin alfa BS Injection [MYL]. 2019. https://www.pmda.go.jp/drugs/2019/P20191011003/730869000_30100AMX00280_A100_1.pdf.pdf Accessed 13 Oct 2023 (in Japanese).

  55. Pharmaceuticals and Medical Devices Agency. Review report for Insulin lispro BS Injection [Sanofi]. 2020. https://www.pmda.go.jp/drugs/2020/P20200402003/780069000_30200AMX00421_A100_1.pdf. Accessed 15 Oct 2023 (in Japanese).

  56. Shiramoto M, Yoshihara T, Schmider W, Takahashi Y, Nowotny I, Kajiwara M, et al. Similar pharmacokinetics and pharmacodynamics of biosimilar SAR342434 insulin lispro and Japan-approved Humalog insulin lispro in healthy Japanese subjects. Clin Pharmacol Drug Dev. 2022;11(6):754–60. https://doi.org/10.1002/cpdd.1068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Pharmaceuticals and Medical Devices Agency. Review report for Adalimumab BS SC Injection [FKB]. 2020. https://www.pmda.go.jp/drugs/2020/P20200624002/230971000_30200AMX00466_A100_1.pdf. Accessed 14 Oct 2023 (in Japanese).

  58. Yonemura T, Yazawa R, Haranaka M, Kawakami K, Takanuma M, Kanzo T, et al. Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants. BMC Pharmacol Toxicol. 2022;23(1):6. https://doi.org/10.1186/s40360-021-00545-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Puri A, Niewiarowski A, Arai Y, Nomura H, Baird M, Dalrymple I, et al. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects. Br J Clin Pharmacol. 2017;83(7):1405–15. https://doi.org/10.1111/bcp.13245.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Pharmaceuticals and Medical Devices Agency. Review report for Adalimumab BS SC Injection [Daiichi sankyo]. 2021. https://www.pmda.go.jp/drugs/2021/P20210122001/430574000_30300AMX00017_A100_2.pdf. Accessed 15 Oct 2023 (in Japanese).

  61. Kaur P, Chow V, Zhang N, Moxness M, Kaliyaperumal A, Markus R. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis. 2017;76(3):526–33. https://doi.org/10.1136/annrheumdis-2015-208914.

    Article  CAS  PubMed  Google Scholar 

  62. Pharmaceuticals and Medical Devices Agency. Review report for Adalimumab BS SC Injection [MA]. 2021. https://www.pmda.go.jp/drugs/2021/P20210324004/790005000_30300AMX00236_A100_1.pdf. Accessed 15 Oct 2023 (in Japanese).

  63. Park KR, Chung H, Yang SM, Lee S, Yoon SH, Cho JY, et al. A randomized, double-blind, single-dose, two-arm, parallel study comparing pharmacokinetics, immunogenicity and tolerability of branded adalimumab and its biosimilar LBAL in healthy male volunteers. Expert Opin Investig Drugs. 2017;26(5):619–24. https://doi.org/10.1080/13543784.2017.1307339.

    Article  CAS  PubMed  Google Scholar 

  64. Pharmaceuticals and Medical Devices Agency. Review report for Adalimumab BS SC Injection [CTNK]. 2023. https://www.pmda.go.jp/drugs/2023/P20231010001/530191000_30500AMX00239_A100_1.pdf. Accessed 15 Oct 2023 (in Japanese).

  65. Haranaka M, Tanaka T, Kim S, Bae Y, Jeon D, Choi E, Cha J, Lee S, Ogama Y. Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults. Immunotherapy. 2023;15(3):149–61. https://doi.org/10.2217/imt-2022-0181.

    Article  CAS  PubMed  Google Scholar 

  66. Pharmaceuticals and Medical Devices Agency. Review report for Insulin aspart BS Injection [Sanofi]. 2021. https://www.pmda.go.jp/drugs/2021/P20210408001/780069000_30300AMX00240_A001_1.pdf. Accessed 15 Oct 2023 (in Japanese).

  67. Shiramoto M, Yoshihara T, Schmider W, Takagi H, Nowotny I, Kajiwara M, et al. Pharmacokinetic and pharmacodynamic similarity between SAR341402 insulin aspart and Japan-approved NovoRapid in healthy Japanese subjects. Sci Rep. 2021;11(1):22931. https://doi.org/10.1038/s41598-021-02410-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Pharmaceuticals and Medical Devices Agency. Review report for Pegfilgrastim BS SC Injection [Mochida] and [Nipro]. 2023. https://www.pmda.go.jp/drugs/2023/P20230922001/790250000_30500AMX00271_A100_1.pdf. Accessed 15 Oct 2023 (in Japanese).

  69. Pharmaceuticals and Medical Devices Agency. Review report for Ustekinumab BS SC Injection [F]. 2023. https://www.pmda.go.jp/drugs/2023/P20230915001/670109000_30500AMX00238_A100_1.pdf. Accessed 15 Oct 2023 (in Japanese).

  70. Wynne C, Hamilton P, McLendon K, Stroissnig H, Smith M, Duijzings P, et al. A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults. Expert Opin Investig Drugs. 2023;32(5):417–27. https://doi.org/10.1080/13543784.2023.2215426.

    Article  CAS  PubMed  Google Scholar 

  71. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–20. https://doi.org/10.1136/annrheumdis-2012-203090.

    Article  CAS  PubMed  Google Scholar 

  72. Cohen SB, Alten R, Kameda H, Hala T, Radominski SC, Rehman MI, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther. 2018;20(1):155. https://doi.org/10.1186/s13075-018-1646-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017;4(8):e350–61. https://doi.org/10.1016/S2352-3026(17)30106-0.

    Article  PubMed  Google Scholar 

  74. Sharman JP, Liberati AM, Ishizawa K, Khan T, Robbins J, Alcasid A, et al. A randomized, double-blind, efficacy and safety study of PF-05280586 (a rituximab biosimilar) compared with rituximab reference product (MabThera®) in subjects with previously untreated CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL). BioDrugs. 2020;34(2):171–81. https://doi.org/10.1007/s40259-019-00398-7.

    Article  CAS  PubMed  Google Scholar 

  75. Matsuno H, Tomomitsu M, Hagino A, Shin S, Lee J, Song YW. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. Ann Rheum Dis. 2018;77(4):488–94. https://doi.org/10.1136/annrheumdis-2017-212172.

    Article  CAS  PubMed  Google Scholar 

  76. Yamanaka H, Kamatani N, Tanaka Y, Hibino T, Drescher E, Sánchez-Bursón J, et al. A comparative study to assess the efficacy, safety, and immunogenicity of YLB113 and the etanercept reference product for the treatment of patients with rheumatoid arthritis. Rheumatol Ther. 2020;7(1):149–63. https://doi.org/10.1007/s40744-019-00186-3.

    Article  PubMed  Google Scholar 

  77. Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 2017;18(7):917–28. https://doi.org/10.1016/S1470-2045(17)30434-5.

    Article  CAS  PubMed  Google Scholar 

  78. von Minckwitz G, Colleoni M, Kolberg HC, Morales S, Santi P, Tomasevic Z, et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2018;19(7):987–98. https://doi.org/10.1016/S1470-2045(18)30241-9.

    Article  Google Scholar 

  79. Pegram MD, Bondarenko I, Zorzetto MMC, Hingmire S, Iwase H, Krivorotko PV, et al. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. Br J Cancer. 2019;120(2):172–82. https://doi.org/10.1038/s41416-018-0340-2.

    Article  CAS  PubMed  Google Scholar 

  80. Reinmuth N, Bryl M, Bondarenko I, Syrigos K, Vladimirov V, Zereu M, et al. PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin®), both plus paclitaxel and carboplatin, as first-line treatment for advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study. BioDrugs. 2019;33(5):555–70. https://doi.org/10.1007/s40259-019-00363-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares Rodriguez L, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind. Phase III study Clin Cancer Res. 2019;25(7):2088–95. https://doi.org/10.1158/1078-0432.CCR-18-2702.

    Article  CAS  PubMed  Google Scholar 

  82. Trukhin D, Poddubskaya E, Andric Z, Makharadze T, Bellala RS, Charoentum C, et al. Efficacy, safety and immunogenicity of MB02 (bevacizumab Biosimilar) versus reference bevacizumab in advanced non-small cell lung cancer: a randomized, double-blind, Phase III study (STELLA). BioDrugs. 2021;35(4):429–44. https://doi.org/10.1007/s40259-021-00483-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Verschraegen C, Andric Z, Moiseenko F, Makharadze T, Shevnya S, Oleksiienko A, et al. Candidate bevacizumab biosimilar CT-P16 versus European Union Reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer: a randomized controlled trial. BioDrugs. 2022;36(6):749–60. https://doi.org/10.1007/s40259-022-00552-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Hagino H, Narita R, Yokoyama Y, Watanabe M, Tomomitsu M. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis. Osteoporos Int. 2019;30(10):2027–37. https://doi.org/10.1007/s00198-019-05038-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Nishi S, Yamada M, Tsuruya K, Masakane I, Nakamoto H. JR-131, a biosimilar of darbepoetin alfa, for the treatment of hemodialysis patients with renal anemia: a randomized, double-blinded, parallel-group phase 3 study. Ther Apher Dial. 2020;24(2):126–35. https://doi.org/10.1111/1744-9987.13422.

    Article  CAS  PubMed  Google Scholar 

  86. Lee JH, Ha Chung B, Joo KW, Shin SK, Kim YL, Na KY, et al. Efficacy and safety of CKD-11101 (darbepoetin-alfa proposed biosimilar) compared with NESP in anaemic chronic kidney disease patients not on dialysis. Curr Med Res Opin. 2019;35(6):1111–8. https://doi.org/10.1080/03007995.2018.1560134.

    Article  PubMed  Google Scholar 

  87. Genovese MC, Glover J, Greenwald M, Porawska W, El Khouri EC, Dokoupilova E, et al. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Arthritis Res Ther. 2019;21(1):281. https://doi.org/10.1186/s13075-019-2046-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679–87. https://doi.org/10.1136/annrheumdis-2016-210459.

    Article  CAS  PubMed  Google Scholar 

  89. Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76(6):1093–102. https://doi.org/10.1016/j.jaad.2016.12.014.

    Article  CAS  PubMed  Google Scholar 

  90. Matsuno H, Kang YM, Okada M, Lee SI, Park SH, Sheen DH, et al. Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: a 52-week phase III randomised study. Clin Exp Rheumatol. 2022;40(5):1025–33. https://doi.org/10.55563/clinexprheumatol/cyudn8.

    Article  PubMed  Google Scholar 

  91. Kay J, Jaworski J, Wojciechowski R, Wiland P, Dudek A, Krogulec M, et al. Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Res Ther. 2021;23(1):51. https://doi.org/10.1186/s13075-020-02394-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Pharmaceuticals and Medical Devices Agency. Review report for Ranibizumab BS ITV Injection [Senju]. 2021. https://www.pmda.go.jp/drugs/2021/P20210909002/380086000_30100AMX00243_A100_1.pdf. Accessed 15 Oct 2023 (in Japanese).

  93. Feldman SR, Reznichenko N, Berti F, Duijzings P, Ruffieux R, Otto H, et al. Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. Expert Opin Biol Ther. 2023;23(8):759–71. https://doi.org/10.1080/14712598.2023.2235263.

    Article  CAS  PubMed  Google Scholar 

  94. IPRP Biosimilars Working Group (BWG) Workshop. Increasing the efficiency of biosimilar development programs—reevaluating the need for comparative clinical efficacy studies. https://www.fda.gov/media/172197/download. Accessed 15 Oct 2023.

  95. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2006. https://www.ema.europa.eu/en/documents/scientific-guideline/annex-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins_en.pdf. Accessed 15 Oct 2023.

  96. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing low molecular-weight-heparins. 2016. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-clinical-development-similar-biological-medicinal-products-containing-low_en.pdf. Accessed 15 Oct 2023.

  97. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. 2015. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-clinical-development-similar-biological-medicinal-products-containing_en-0.pdf. Accessed 15 Oct 2023.

  98. US FDA. BsUFA III Regulatory Research Pilot Program: Research Roadmap. 2023. https://www.fda.gov/media/164751/download. Accessed 15 Oct 2023.

  99. Ministry of Health, Labour and Welfare. Questions and Answers (Q&A) on guideline for ensuring the quality, safety, and efficacy of biosimilars. 2024. https://www.pmda.go.jp/files/000267480.pdf. Accessed 27 Mar 2024.

  100. Woollett GR, Park JP, Han J, Jung B. The role of PD biomarkers in biosimilar development - To get the right answer one must first ask the right question. Clin Pharmacol Ther. 2023;113(1):50–4. https://doi.org/10.1002/cpt.2753.

    Article  CAS  PubMed  Google Scholar 

  101. Strauss DG, Wang YM, Florian J, Zineh I. Pharmacodynamic biomarkers evidentiary considerations for biosimilar development and approval. Clin Pharmacol Ther. 2023;113(1):55–61. https://doi.org/10.1002/cpt.2761.

    Article  CAS  PubMed  Google Scholar 

  102. Guillen E, Ekman N, Barry S, Weise M, Wolff-Holz E. A data driven approach to support tailored clinical programs for biosimilar monoclonal antibodies. Clin Pharmacol Ther. 2023;113(1):108–23. https://doi.org/10.1002/cpt.2785.

    Article  CAS  PubMed  Google Scholar 

  103. Luke MC. Equivalence of locally acting drug products. 2017. https://www.fda.gov/media/105890/download Accessed 15 Oct 2023.

  104. Novakovic J, Szirtes J, Fields A, Tsang YC. Clinical endpoint bioequivalence studies are not sensitive: a perspective from generic drugs. Clin Pharmacol Ther. 2019;105(2):295–7. https://doi.org/10.1002/cpt.1244.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Office of Cellular and Tissue-Based Products, Pharmaceuticals and Medical Devices Agency, 3-3-2, Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan

    Ryosuke Kuribayashi, Aya Hariu, Ayuki Nakano & Yasuhiro Kishioka

  2. Office of Regulatory Science Research, Pharmaceuticals and Medical Devices Agency, 3-3-2, Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan

    Ryosuke Kuribayashi

Authors
  1. Ryosuke Kuribayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aya Hariu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ayuki Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuhiro Kishioka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryosuke Kuribayashi.

Ethics declarations

Funding

No external funding was used for the preparation of this manuscript.

Conflict of interest

Ryosuke Kuribayashi, Aya Hariu, Ayuki Nakano, and Yasuhiro Kishioka declare they have no conflicts of interest that might be relevant to the contents of this article.

Consent for publication

Not applicable.

Consent for participation

Not applicable.

Author contributions

RK was the main author of this article. RK, AH, AN, and YK contributed to the fact-finding and editing of this article. All authors have read and approved the final manuscript.

Ethics approval

Not applicable.

Availability of data and materials

Not applicable.

Code availability

Not applicable.

Additional information

The views expressed in this article are those of the authors and do not necessarily reflect the official views of the PMDA.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kuribayashi, R., Hariu, A., Nakano, A. et al. Survey of Data Package and Sample Size of Comparative Clinical Studies for Biosimilar Developments from PMDA Assessments. Pharm Med (2024). https://doi.org/10.1007/s40290-024-00525-y

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40290-024-00525-y

Search

Navigation